As a public service to our readership, this article - peer reviewed by the Editors of EuroIntervention - has been published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors, and not that of the journal or its publishers.
Please note that supplementary movies are not available online at this stage. Once a paper is published in its edited and formatted form, it will be accompanied online by any supplementary movies.
To read the full content of this article, please log in to download the PDF.
Bioresorbable vascular scaffolds (BVS) allow the treatment of coronary lesions by offering vascular support and antiproliferative drug release without the need to implant a permanent metal layer in the coronary vessel. A problem occasionally observed during the follow-up is late fracture or late structural discontinuity(1,2). Although severe BVS dismantling has been associated with an increased risk of late BVS-thrombosis the implications of this phenomenon still remain unsettled(1,2). The use of BVS in patients with in-stent restenosis (ISR) has been demonstrated to be feasible, safe, and effective(3). However, implications of late BVS dismantling in patients treated for ISR currently ...
Sign in to read and download the full articleForgot your password?
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com